Showing 1338 results
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LRThird quarterQ3 net sales grew +4% (cc¹, +4% USD), with core operating income¹ +10% (cc, +11% USD)Sales growth driven by priority brands including Kisqali (+…
-
Ad hoc release /Ad-hoc-Mitteilung gemäss Art. 53 KRDrittes QuartalDer Nettoumsatz stieg im dritten Quartal um +4% (kWk¹, +4% USD), das operative Kernergebnis¹ verbesserte sich um +10% (kWk, +11% USD)Das…
-
Press release /Remibrutinib achieved significant and clinically meaningful reduction in relapses vs. teriflunomide, to approximately 1 relapse every 13 years, without the need for chronic B-cell depletion¹˒²MRI…
-
Press release /Six-year NATALEE analysis showed ~20% reduction in risk of death compared to ET alone1 Benefit increased over time in invasive disease-free survival and across key secondary endpoints1-3 Patients off…
-
Press release /Cosentyx® (secukinumab) becomes first and only IL-17A inhibitor approved in Europe for adults with PMR,1 a common inflammatory rheumatic disease with limited advanced treatment options2-6Approval…
-
Press release /In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with responses seen by Week 21SD is most prevalent type of chronic inducible…
-
Press release /Late-breaking data from positive Phase III REMODEL-1/-2 trials will show efficacy and safety profile of remibrutinib in RMS Novartis to hold virtual investor event highlighting REMODEL data and…
-
Press release /If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹Recommendation based…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options Del-…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Basel, September 4, 2026 – Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not…